covid
Buscar en
Progresos de Obstetricia y Ginecología
Toda la web
Inicio Progresos de Obstetricia y Ginecología Diagnóstico prenatal del retraso de crecimiento intrauterino mediante marcadore...
Journal Information
Vol. 47. Issue 5.
Pages 207-213 (January 2004)
Share
Share
Download PDF
More article options
Vol. 47. Issue 5.
Pages 207-213 (January 2004)
Full text access
Diagnóstico prenatal del retraso de crecimiento intrauterino mediante marcadores bioquímicos
Biochemical markers in the prenatal diagnosis of intrauterine growth retardation
Visits
8086
M.D. Gómezaa,
Corresponding author
lolagomez@eresmas.com

Servicio de Obstetricia y Ginecología. Hospital Universitario Sant Joan de Déu. Passeig Sant Joan de Déu, 2. 08950 Esplugues. Barcelona. España
, S. Ferreroa, C. Vallsb, J. Poncea, E. Miróa, M. Borrása, J.M. Laïllaa
a Servicio de Obstetricia y Ginecología. Hospital Universitario Sant Joan de Déu. Esplugues. Barcelona
b Departamento de Hormonas. Laboratorio. Hospital Universitario de Sant Joan de Déu. Esplugues. Barcelona. España
This item has received
Article information
Resumen
Objetivo

Determinar la relación y capacidad diagnóstica de la IGF-I (insulin-like growth factor I), IGFBP-I (insulin-like growth factor binding protein I), leptina, y alfa-fetoproteína (AFP) en líquido amniótico de 14-18 semanas con el desajuste ponderal del feto al nacer.

Sujetos y métodos

Estudio longitudinal y prospectivo. Gestantes con amniocentesis de 14-18 semanas. 86 controles, 18 RCIU (retraso de crecimiento intrauterino) < percentil 10, y 17 RCIU < percentil 5.

Resultados

No se demuestra una correlación significativa entre el RCIU y la IGF-I, la IGFBP-I, y la leptina. La AFP cumple una correlación inversa con la severidad del RCIU; en el RCIU < percentil 10 presentó: sensibilidad (S), 65,7%; especificidad (E), 56,9%; valor predictivo positivo (VPP), 38,3%; valor predictivo negativo (VPN), 80,3%, y una capacidad global del 65,6%. En el RCIU < percentil 5 se obtuvo: S, 76,4%; E, 54,8%; VPP, 21,6%; VPN, 93,4%, y una capacidad global del 70,6%. Conclusión: Los valores elevados de AFP en líquido amniótico de diagnóstico prenatal pueden contribuir a la detección precoz de la población con riesgo de desarrollar un RCIU.

Palabras clave:
Retraso de crecimiento intrauterino
Insulin-like growth factor I
Insulin-like growth factor binding protein I
Leptina
Alfa-fetoproteína
Abstract
Objective

To determine the relationship between intrauterine growth retardation (IUGR) and insulinlike growth factor-1 (IGF-I), IGF binding protein-1 (IGFBP-I), leptin, and alfa-fetoprotein (AFP) levels in amniotic fluid after 14-18 weeks of gestation, and to assess the diagnostic utility of these biochemical markers.

Subjects and methods

We performed a longitudinal, prospective study. Amniocentesis was performed in pregnant women after 14-18 weeks of gestation. The study population consisted of 86 controls, 18 IUGR<10 percentile, and 17 IUGR<5 percentile.

Results

No significant correlation was found between the severity of IUGR and IGF-I, IGFBP-I, or leptin. AFP was inversely correlated with the severity of IUGR; the results for IUGR<10 percentile were: sensitivity: 65.7%, specificity: 56.9%, positive predictive value: 38.3%, negative predictive value: 80.3%, and an overall diagnostic capacity of 65.6%. The results for the IUGR<5 percentile were: sensitivity: 76.4%, specificity: 54.8%, positive predictive value: 21.6%, negative predictive value: 93.4%, and an overall diagnostic capacity of 70.6%.

Conclusion

Elevated values of AFP in amniotic fluid may help in the early detection of populations at risk for IUGR.

Keywords:
Intrauterine growth retardation
Insulin-like growth factor I
Insulin-like growth factor binding protein I
Leptin
Alpha-fetoprotein
Full text is only aviable in PDF
Bibliografía
[1.]
J. Leger, M. Noel, J.M. Limal, P. Czernichow.
Growth factors and intrauterine growth retardation. I. Serum growth hormone, insulin- like growth factor (IGF)-I, IGF-II, and IGF binding protein 3 levels in normally grown and growth-retarded human fetuses during the second half of gestation.
Pediatr Res, 40 (1996), pp. 94-100
[2.]
A. Wiznitzer, E.A. Reece, C. Homko, B. Furman, M. Mazor, J. Levy.
Insulin-like growth factors, their binding proteins, and fetal macrosomia in offspring of nondiabetic pregnant women.
Am J Perinatol, 15 (1998), pp. 23-28
[3.]
S. Cianfarani, D. Germani, L. Rossi, G. Argiro, S. Boemi, M. Lemon, et al.
IGF-I and IGF-binding protein-1 are related to cortisol in human cord blood.
Eur J Endocrinol, 138 (1998), pp. 524-529
[4.]
R. Holmes, R. Montemagno, J. Jones, M. Preece, C. Rodeck, P. Soothill.
Fetal and maternal plasma insulin-like growth factors and binding proteins in pregnancies with appropriate or retarded fetal growth.
Early Hum Dev, 49 (1997), pp. 7-17
[5.]
D. Klauwer, W.F. Blum, S. Hanitsch, W. Rascher, P.D. Lee, W. Kiess.
IGF-I, IGF-II, free IGF-I and IGFBP-1, -2 and -3 levels in venous cord blood: relationship to birthweight, length and gestational age in healthy newborns.
Acta Paediatr, 86 (1997), pp. 826-833
[6.]
M. Osorio, J. Torres, F. Moya, J. Pezzullo, C. Salafia, R. Baxter, et al.
Insulin-like growth factors (IGFs) and IGF binding proteins -1, -2, and -3 in newborn serum: relationships to fetoplacental growth at term.
Early Hum Dev, 46 (1996), pp. 15-26
[7.]
J. Ponce.
Avaluació dels nivells en líquid amniòtic de la IGF-I i la IGFBP-I en fetus afectats per retard de creixement intrauterí (tesi doctoral).
Universitat Autònoma de Barcelona, (1998),
[8.]
L.D. Nonoshita, N.C. Wathen, B.A. Dsupin, T. Chard, L.C. Giudice.
Insulin-like growth factors (IGFs), IGF-binding proteins (IGFBPs), and proteolyzed IGFBP-3 in embryonic cavities in early human pregnancy: their potential relevance to maternalembryonic and fetal interactions.
J Clin Endocrinol Metab, 79 (1994), pp. 1249-1255
[9.]
F.M. Reis, P. Florio, L. Cobellis, S. Luisi, F.M. Severi, C. Bocchi, et al.
Human placenta as a source of neuroendocrine factors.
Biol Neonate, 79 (2001), pp. 150-156
[10.]
C.J. Ashworth, N. Hoggard, L. Thomas, J.G. Mercer, J.M. Wallace, R.G. Lea.
Placental leptin.
Rev Reprod, 5 (2000), pp. 18-24
[11.]
I. Cetin, P.S. Morpurgo, T. Radaelli, E. Taricco, D. Cortelazzi, M. Bellotti, et al.
Fetal plasma leptin concentrations relationship with different intrauterine growth patterns from 19 weeks to term.
Pediatr Res, 48 (2000), pp. 646-651
[12.]
L. Gómez, A. Carrascosa, D. Yeste, N. Potau, S. Rique, P. Ruiz-Cuevas, et al.
Leptin values in placental cord blood of human newborns with normal intrauterine growth after 30-42 weeks of gestation.
Horm Res, 51 (1999), pp. 10-14
[13.]
T. Ertl, S. Funke, I. Sarkany, I. Szabo, W. Rascher, W.F. Blum, et al.
Postnatal changes of leptin levels in full-term and preterm neonates: their relation to intrauterine growth, gender and testosterone.
Biol Neonato, 75 (1999), pp. 167-176
[14.]
T.K. Hytinantti, H.A. Koistinen, K. Teramo, S.L. Karonen, V.A. Koivisto, S. Andersson.
Increased fetal leptin in type I diabetes mellitus pregnancies complicated by chronic hypoxia.
Diabetologia, 43 (2000), pp. 709-713
[15.]
C. Schubring, W. Kiess, P. Englaro, W. Rascher, J. Dotsch, S. Hanitsch, et al.
Levels of leptin in maternal serum, amniotic fluid, and arterial and venous cord blood: relation to neonatal and placental weight.
J Clin Endocrinol Metab, 82 (1997), pp. 1480-1483
[16.]
C. Schubring, W. Kiess, P. Englaro, W. Rascher, W. Blum.
Leptin concentrations in amniotic fluid, venous and arterial cord blood and maternal serum: high leptin synthesis in the fetus and inverse correlation with placental weight.
Eur J Pediatr, 155 (1996), pp. 830
[17.]
B.F. Crandall, L. Robinson, P. Grau.
Risks associated with an elevated maternal serum alpha-fetoprotein level.
Am J Obstet Gynecol, 165 (1991), pp. 94
[18.]
G. Huerta-Enochian, V. Katz, S. Erfurth.
The associaton of abnormal alpha-fetoprotein and adverse pregnancy oitcome: does increased fetal surveillance affect pregnancy outcome?.
Am J Obstet Gynecol, 184 (2001), pp. 1549-1553
[19.]
E. Verspyck, S. Degre, M.F. Hellot, G. Descargues, C. Philippe, G. Labadie, et al.
Amniotic fluid alpha-fetoprotein is not a useful biological maker of pregnancy outcome.
Prenat Diagn, 19 (1999), pp. 1031-1034
[20.]
Y. Ochshorn, M.J. Kupferminc, A. Eldor, I. Wolman, J.B. Lessing, Y. Yaron.
Second trimester materna serum alpha-fetoprotein is elevated in women with adverse pregnancy outcome associated with inherited thrombophilias.
Prenat Diagn, 21 (2001), pp. 658-661
[21.]
E. González Bosquet, M.J. Cerqueira, M. Pérez Quintana, M. Cuerda, L.L. Cabero.
Relación entre el peso de nacimiento y la edad de gestación en una población de recién nacidos del Hospital Materno Infantil del Valle de Hebrón.
Prog Obst Gin, 38 (1995), pp. 162-167
[22.]
B. Chevallier, A. Lagarde, H. Degrelle, J. Belaisch-Allart, P. Giraudet, J.P. Gallet.
Insulin-like growth factor binding protein 1 level in amniotic fluid: correlation with birth weight.
Biol Neonate, 73 (1998), pp. 404-406
[23.]
Y. Ohnishi, C. Yamashiro, T. Yanagihara, T. Hata.
Hepatocite growth factor concentration inthe early second-trimester amniotic fluid does not predict fetal growth at birth.
Hum Reprod, 14 (1999), pp. 2625-2628
[24.]
J. Verhaeghe, W. Coopmans, E. Van Herck, D. Van Schoubroeck, J.A. Deprest, I. Witters.
IGF-I, IGF-II, IGF binding protein 1, and C-peptide in second trimester amniotic fluid are dependent on gestational age but do not predict weight at birth.
Pediatr Res, 46 (1999), pp. 101-108
[25.]
S. Cho, K.K. Durfee, B.A. Keel, L.H. Parks.
Perinatal outcomes in a prospective matched pair study of pregnancy and unexplained elevatedor low AFP screening.
J Perinat Med, 25 (1997), pp. 476-483
[26.]
Y. Yaron, M. Cherry, R.L. Kramer, J.E. O’Brien, M. Hallak, M.P. Johnson, et al.
Second-trimester maternal serummarker screening: maternal serum alpha-protein, beta-humanchorionic gonadotropin, estriol, and their various combinations as predictors of pregnancy outcome.
Am J Obstet Gynecol, 181 (1999), pp. 968-974
Copyright © 2004. Sociedad Española de Ginecología y Obstetricia
Download PDF
Article options
es en pt

¿Es usted profesional sanitario apto para prescribir o dispensar medicamentos?

Are you a health professional able to prescribe or dispense drugs?

Você é um profissional de saúde habilitado a prescrever ou dispensar medicamentos